At year 5, a better improvement from baseline in VAS pain was observed in the MRI treat-to-target group compared with the conventional treat-to-target group (borderline significant at year 2).
← all excerpts
Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial.
1
—
—